We are live on
!
Find out more
BC
Birchview Capital Portfolio holdings
AUM
$176M
1-Year Est. Return
95.04%
This Fund
S&P 500
This Quarter
Est. Return
+0.66%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$167M
AUM Growth
-$1.27M
(-0.75%)
Cap. Flow
+$3.86M
Cap. Flow
% of AUM
2.31%
Top 10 Holdings %
Top 10 Hldgs %
72.22%
Holding
63
New
9
Increased
5
Reduced
4
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Prothena Corp
PRTA
|
+$944K |
| 2 |
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
|
+$591K |
| 3 |
Acadia Pharmaceuticals
ACAD
|
+$506K |
| 4 |
Zentalis Pharmaceuticals
ZNTL
|
+$428K |
| 5 |
Elutia
ELUT
|
+$346K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cullinan Oncology
CGEM
|
+$461K |
| 2 |
Nektar Therapeutics
NKTR
|
+$369K |
| 3 |
YTEN
Yield10 Bioscience, Inc. Common Stock
YTEN
|
+$238K |
| 4 |
BLUE
bluebird bio
BLUE
|
+$46K |
| 5 |
Ovintiv
OVV
|
+$4.03K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 96.67% |
| 2 | Energy | 1.69% |
| 3 | Consumer Staples | 0.25% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
DRNA
51
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $373K | 0.22% |
10,000
| – | – |
|
|
FOLD
52
DELISTED
Amicus Therapeutics
FOLD
| $366K | 0.22% |
38,000
| – | – |
|
|
SIEN
53
DELISTED
Sientra, Inc.
SIEN
| $318K | 0.19% |
+4,000
| New | +$284K |
|
54
BioCryst Pharmaceuticals
BCRX
$2.34B
| $316K | 0.19% |
20,000
| – | – |
|
|
55
Elutia
ELUT
$42M
| $288K | 0.17% |
+30,000
| New | +$346K |
|
56
Kiniksa Pharmaceuticals
KNSA
$4.83B
| $279K | 0.17% |
+20,000
| New | +$304K |
|
57
Arcutis Biotherapeutics
ARQT
$3.52B
| $246K | 0.15% |
9,000
| – | – |
|
58
InflaRx
IFRX
$271M
| $208K | 0.12% |
70,000
| – | – |
|
59
Cytokinetics
CYTK
$10.9B
| $198K | 0.12% |
+10,000
| New | +$235K |
|
|
HOOK
60
DELISTED
HOOKIPA Pharma
HOOK
| $183K | 0.11% |
+2,000
| New | +$267K |
|
61
TherapeuticsMD
TXMD
$23.8M
| $119K | 0.07% |
2,000
| – | – |
|
|
CNCE
62
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
| $84K | 0.05% |
20,000
| – | – |
|
|
YTEN
63
DELISTED
Yield10 Bioscience, Inc. Common Stock
YTEN
| – | – |
-790
| Closed | -$238K |
|
Similar funds
RWA
BAM
TIM
TFCM
FPW
LWM
PFA
DAM
Birchview Capital's Q2 2021 Portfolio in Review
As of Q2 2021, Birchview Capital held 63 positions worth $167M, down 0.75% from $168M the previous quarter. Its ten largest holdings account for 72% of the portfolio.
Birchview Capital's Q2 2021 filing shows 9 new, 5 increased, 4 reduced and 1 closed positions. Its largest new stake was Prothena Corp: 30,247 shares worth $1.55M. The largest sale was Cullinan Oncology, an estimated $461K.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier, followed by Energy and Consumer Staples.
- Birchview Capital's largest Q2 2021 buy was Prothena Corp: 30,247 shares worth $1.55M.
- Birchview Capital added most to Acadia Pharmaceuticals in Q2 2021, an estimated $506K increase.
- Birchview Capital's biggest Q2 2021 reduction was Cullinan Oncology, cutting an estimated $461K.
- Birchview Capital fully exited Yield10 Bioscience, Inc. Common Stock in Q2 2021, selling an estimated $238K.
- Birchview Capital's ten largest holdings make up 72% of its $167M portfolio in Q2 2021.
- Birchview Capital opened 9 new positions and closed 1 in Q2 2021.
- Birchview Capital's portfolio value fell 0.75% quarter-over-quarter to $167M.
Based on Birchview Capital's 13F filing for Q2 2021, filed 10 Aug 2021.